Spectral AI shares surge 21.21% after-hours on Q4 profit, $31.7M BARDA funding, and $18.5M 2026 revenue guidance.

Spectral AI surged 21.21% in after-hours trading following the release of Q4 2025 financial results, which included a $0.6 million net income—a sharp turnaround from a $7.7 million loss in Q4 2024—and a $15.4 million cash balance. The company also announced $31.7 million in non-dilutive BARDA funding for its DeepView burn diagnostics system, bringing total BARDA support to $54.9 million under a $150 million contract. Guidance for $18.5 million in 2026 revenue, though excluding commercial sales of DeepView, signaled progress toward commercialization. CEO Vincent Capone highlighted the De Novo 510(k) FDA submission and improved financial efficiency, reinforcing investor confidence in the company’s strategic pivot from R&D funding to product readiness.